Ready-to-Use Cell-Based Assays
The Cell-Based Assay market is projected to continue double digit growth over the next several years. One of the major challenges facing the development and manufacturing of Cell based assay products for drug discovery and development is the difficulty associated with preserving the cells and the integrity of cell junctions during the transportation and storage of the finished kits. There are numerous Cell based assay Kits available such as cell viability and proliferation. 
A unique proprietary shipping medium has been introduced by ADMEcell that allows for selected cell based assay kits to be shipped in a solid state at room temperature. Once the kits are received, the shipping medium is simply removed by liquefaction at 37oC, and replaced with a fresh medium. The cells are then ready for use in the assay for experimental compounds soon after.
Cell Based Assays such as Caco-2, MDCK and BCRP benefit from this innovative technology. ADMEcell’s Ready-To-Use Cell Based Assay Kits- Ready-to-Use Cell-Based Assays - are shipped at room temperature on a regular basis, providing a unique and convenient tool for accelerating the drug discovery and development process.
As the Cell Based Assay market continues to grow, availability of a shipping medium that allows for shipping Ready-To-Use Cell Based products at room temperature will have a major impact on the availability of the kits that would not have been readily available otherwise.
ADMEcell – 2012 and Beyond
ADMEcell experienced a successful 2011 with the increase in the sales of cell-based assays product line. Cell-based assays continue to be in great demand for large and small pharma companies, biotech companies and research institutions. ADMEcell has recently introduced a ready-to-use cell-based assay for BCRP for drug transporter studies. The BCRP kit fits very well with the ready-to-use ADMEcell Caco-2 and MDCK-MDR-1 kits. The Caco-2 kit has been adapted by numerous biotech companies for their drug development programs. The poster presented by Celgene at the recent AAPS shows how successfully they have adapted the ADMEcell CacoReady kit to their drug discovery program:
http://www.admecell.com/download-the-aaps-cacoready-poster
The cell-based assay market continues to grow at a rate of 10% per year. Almost all of this market is from assays generated in-house at various companies and institutions. The market to provide ready-to-use cell-based assays is just beginning to take off as companies look for sourcing state of the art and ready-to-use assays to assist them in drug discovery and development programs.
ADMEcell continues to add new in vitro models including cell-based assays to its product portfolio. A cell-based assay for blood Brain Barrier holds much promise as a new model to adapt.
ADMEcell’s new research facility has been completed and current development projects are under way to expand ADMEcell’s product line in the preclinical development field. New assays will focus on saving time and increasing accuracy to assist the drug discovery and development process.
ADMEcell To Exhibit At The AAPS Meeting IN Washington DC Oct 25-27
ADMEcell will join over 500 exhibitors at the upcoming AAPS meeting in Washinton DC October 25 through October 27. This is the 25th anniversary of the AAPS meeting which will include speakers such as Janet Woodcock, M.D., director of the Center for Drug Evaluatio
n and Research at the Food and Drug Administration, who will provide her view on the future of regulations. John Lechleiter, Ph.D., president and chief executive officer, Eli Lilly and Company, will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health, will speak on current research that may lead to new therapies in the future. Sir Michael Rawlins, M.D., chairman of the National Institute of Health & Clinical Excellence (NICE) of the United Kingdom, will speak on the cost benefits of therapies and the societal ability to pay for the therapies, "Value for Money in Healthcare: The Future." NICE is an independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health.
ADMEcell will showcase its three product lines for providing tools for drug discovery and development:
Cell based Assays: Caco-2, MDR-1, BCRP & BBB Permeability
http://www.admecell.com/assays-cellbased/
ELISA Kits For Monoclonal Antibody Assessment: Quantification kits for Human, Mouse, Rat & Bovine IgG and Mouse Ig Isotyping
http://www.admecell.com/assays-elisabased/
Protein Binding Kits For HAS and AGP
http://www.admecell.com/assays-transil/
Please plan to visit us at Exhibit #1559
The ADME Tox in vitro human testing market is estimated at over $500 million in 2011 with a healthy growth rate over 15% per year through 2015. This market is made up of CYP450 inhibition assays, human PK predictive assays, Liver Hepatocytes and Cell-Based Assays such as Caco-2, MDR-1 BCRP and BBB (Blood Brain Barrier), to name a few ( http://www.admecell.com/assays-cellbased/). The largest share of the market is Hepatocytes testing as they closely resemble the in vivo testing. Currently, Pharma and Biotech companies rely heavily on making these assays in house. With Ready To Use Assay Kits for common applications such as Caco-2, MDR-1, BCRP and BBB, the Pharma and Biotech companies could save enormous amounts of time and resources in their drug discovery and development processes.
The future of Ready-to-Use In Vitro Assay Kits is bright. Additional assay development in the drug transporters field will lead to more available Ready to Use Kits.
www.admecell.com
The economic recession has not inhibited the growth of FDA approved antibody drugs and the market for these drugs. So far treatments for Cancer, Arthritis, Autoimmune diseases and Transplant rejection have dominated the class of drugs derived from monoclonal antibodies. The future products will include additional drugs for treatment of the above diseases and others such as Osteoporosis and Asthma.
Monoclonal antibody derived therapeutics have become a significant part of the overall drug market boasting over $40 billion in sales as of 2010 and is likely to double in the next ten years. The development of monoclonal antibodies continues to grow and clearly, faster ready-to-use kits to help rapid determination of the IgG levels in such antibodies remain important tools in the drug discovery and development process.
All major pharmaceutical and biotech companies have active programs in developing monoclonal antibodies. Smaller biotech companies focus on developing such antibodies only, whereas universities and research institutions utilize grants to discover new targets with monoclonal antibody technologies.
ADMEcell and RD-Biotech (Besancon, France) offer a new line of Ready-To-Use 30 minute assay kits to quantitate Human, Mouse, Rat and Bovine IgG in cell culture supernatant, ascites and serum-all assays covering a wide dynamic range (i.e. 16-1000ng/ml for human IgG). Color coded buffer solutions simplify the pipetting steps. Recombinant or fully humanized monoclonal antibodies can be assayed. Also included in the product line is the Mouse IGg sotyping kit.
http://www.admecell.com/assays-elisabased/
DMPK Labs and Integrating New In Vitro Assays
Improve DMPK Productivity by Using the Industry Leading Solution
Determining the Drug Metabolism and PharmacoKinetic properties of a drug is crucial to understanding its safety and efficacy before the regulatory approval process takes place.
Currently, DMPK Labs have a tremendous balancing act on their hands between
getting all the routine work completed with minimal staff and deciding on handling selected new compounds. Many of these compounds can be tested in house or contracted out to CRO. Preparing reagents and developing in-house assays require time and resources, whereas waiting for data from an outside source uses very little resources other than money. However, Ready-to-Use Assay Kits offer a simple solution to balance the resources needed and the associated costs.
So, how does a lab begin to evaluate a newer technology such as a new in vitro assay that can be very helpful long term? In the short term, it seems like there is no time available…However, the benefits for DMPK labs are enormous if they can dedicate some time to evaluate for example, a Ready-To-Use cell based assay such as Caco-2 or MDCR1 or Plasma Protein Binding to compare the cost and time savings with their current methods. These assays are available at a reasonable price and produce speedy and reliable results to make the life easier in the DMPK Labs.
http://www.admecell.com/assays-transil/
http://www.admecell.com/assays-cellbased/
http://www.admecell.com/assays-elisabased/
Accelerate Your Drug Discovery and Development Processes and Control Your Data when Evaluating New Drug Compounds by Using Ready-to-Use Assays
State of the art Ready-to-Use Assays- offered by ADMEcell www.admecell.com eliminate the need for time consuming in-house reagent preparations and assay development, thereby reducing the costs and enhancing the drug discovery and development processes. ADMEcell’s CacoReady and PreadyPort-MDR1 http://www.admecell.com/assays-cellbased/ are examples of Ready-to-Use Assay Kits for generating permeability data for new drug candidates. These assays eliminate the need for in-house cell culture production offering a great deal of cost and time savings. In addition, you will have control on generating your own data without delays. ADMEcell also offers a number of Ready-to-Use products with the same benefits for the assessment of Plasma Protein Binding and Blood Brain Absorption of drug candidates http://www.admecell.com/assays-transil/ Finally, ADMEcell ELISA-Based Ready-to-Use Assay Kits http://www.admecell.com/assays-elisabased/ for quantification of IgG from various species and Mouse Ig Isotyping are available for rapidly and conveniently screening of therapeutic antibodies.
Once a biotech company has decided to implement this strategy, application of the Ready-to-Use Assay Kits will surely become an important part of its long term preclinical development plan.
The increasing need to predict ADME/TOX profiles has led to development of new technologies among which cell based assays are one of the most effective techniques used in almost every phase of drug discovery and development. They are used to study the molecular interactions in a cellular environment and are crucial in compound selections, lead generations,optimization and screening. Cell based assays provide details such as permeability, metabolism, selectivity, combination and most importantly- a toxicity profile.
Cell Based Assays based on measuring transporters across membranes Csuch as Caco-2 and MDR1 assays (to mention a few) are among established methods that are utilized for IND submission for new compounds. The FDA has a list of the necessary studies for transporters.
The market for cell based assays is approaching a billion dollars annually, worldwide with at least a 10% yearly growth rate. Currently, in-house developed assays and CROs are responsible for almost all of the business.
Recently, in vitro assays marketed as Ready-to-Use kits have gained popularity and are becoming more important as biotech and Pharma industries are focused on saving costs of in-house cell culture production and assay development as well as result turnaround time.
Cell based assays based on Ready-to-Use products concept are cost effective, convenient and do not require the end user to maintain a costly and tedious cell culture facility.
ADMEcell's Ready-To-Use Cell Based Assay:
*CacoReady: http://www.admecell.com/cacoready.html?prodid=1 and related products: http://www.admecell.com/assays_cellbased.html – State of the art cell-based assays, providing ease of use and a cost effective in-vitro technology for evaluation of oral absorption efficiency, compound screening, oral bioavailability, mechanisms of oral/intestinal absorption, oral toxicity and transporter studies – all without in-house cell line development, acquisition or propagation;
Welcome to the ADMEcell Blog. As part of our efforts to keep you updated on new developments at ADMEcell, we will be updating this space with product news and special offers from our Executive and Sales teams and new findings, technological news and “Posts from the Bench” from our Lab staff.
ADMEcell, Inc., a life science Company located in the San Francisco Bay Area, was established in October 2008 to develop and market unique and proprietary Ready-to-Use Products that accelerate drug discovery and development processes. The ADMEcell management team combines many years of solid experience in product research, development and marketing in diverse areas of biotechnology, including Molecular Diagnostics, Infectious Diseases, Oncology and Immunodiagnostics. For more details on the management team’s experience and background, please visit: http://www.admecell.com/management.html
ADMEcell’s Ready-to-Use product line includes three major categories:
*CacoReady: http://www.admecell.com/cacoready.html?prodid=1 and related products: http://www.admecell.com/assays_cellbased.html – State of the art cell-based assays, providing ease of use and a cost effective in-vitro technology for evaluation of oral absorption efficiency, compound screening, oral bioavailability, mechanisms of oral/intestinal absorption, oral toxicity and transporter studies – all without in-house cell line development, acquisition or propagation;
*TRANSIL Brain Absorption, Intestinal Absorption and Plasma Protein Binding products: http://www.admecell.com/assays_transil.html – Fast and high-throughput assays for brain tissue binding, brain disposition and plasma protein binding of compounds (including very sticky and tightly bound compounds);
*FastELYSA Antibody Screening products: http://www.admecell.com/assays_elisabased.html – Fast and simple ELISA-based assays for quantification of immunoglobulin G from human and other species, screening of high producing clones, monitoring antibody production, transient transfection and characterization of mouse monoclonal isotypes.
You can always follow us on Twitter @ADMEcell or visit our Facebook page at: http://www.facebook.com/pages/ADMEcell/109021822505525 for the latest updates on our technology and products. Visit our main website at www.admecell.com or send us an e-mail at info@admecell.com
The ADMEcell Management Team